
Article

Biopharmaceutics Classification System (BCS) and Biopharmaceutics Drug Disposition Classification System (BDDCS) – An Approach for Drug Development and Advancement



Tejpal Yadav*

Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University, Rajasthan, Jaipur

Corresponding author: Tejpal Yadav, Department of Pharmaceutics, NIMS Institute of Pharmacy, NIMS University, Rajasthan, Jaipur

ABSTRACT

BCS and Biopharmaceutics Drug disposition Classification System are free, not contending, grouping frameworks that intend to increase, rearrange, and grow drug advancement. Albeit the two frameworks depend on characterizing drugs and new sub-atomic elements into four classes utilizing a similar solubility rules, they contrast in the basis for penetrability and have various purposes. Here, the subtleties and utilizations of the two frameworks are checked on with specific accentuation of their job in drug improvement.

Keywords: drug development, metabolism, brain distribution, permeability, solubility, BCS, BDDCS, drug advancement

INTRODUCTION

The BCS¹ depends on the center thought being that in vitro technique, halfway accepting solubility, and permeability, through capabilities identified with pH and dissolution, may pass the drug items for a rejection of in-vivo bioequivalence considers. The goals of the BCS are to anticipate in vivo execution of medication items from in vitro estimations of solubility and permeability.

In 2005, Wu and Benet³ perceived that for medications displaying more intestinal

penetrability rates, the significant course of disposal in people was through metabolism, while medications showing low intestinal permeability rates were essentially killed in people as unaltered medication within the bile and pee. They recommended that a BDDCS could fill in as a reason for anticipating the significance of carriers in deciding medication demeanor, just as in foreseeing drug–drug associations. The significant contrasts among BDDCS and BCS identify with owns motivation and the estimation for the arrangement as portrayed in the Table-1.

The reasons for BCS are to describe drug molecules for which results of those medications might be qualified for a biowaivers of *in vivo* biological equivalent contemplates. The reason for BDDCS is to anticipate remedydemeanor and capable medication- drug communications in the digestive system and liver, and possibly the kidney and mind. The pair of BCS and BDDCS uses solubility as one of the duplet order rules. The dissolvable boundary used might be known as the solubility of US- FDA, that is, a gauge of the capacity of medication at its most noteworthy portion solidarity to totally dissolve in 250mL of H₂O above a pH range somewhere in the range of 1 and 7.5 at 37°C. For a medication to be viewed as profoundly solvent in the two grouping frameworks, the medication from its most elevated strength administrative endorsed

measurements structure should go totally into the arrangement at its least dissolvability above this pH range in 250mL of H₂O. As we have as of late noted, solubility of US FDA is a property of the medication in a detailing and is definitely not an inborn character of the dynamic drug fixing itself.⁴

The secondae boundary and wherein the pair frameworks contrast, is identified with intestinal permeability. In BDDCS, expectations depend on the intestinal permeability velocity, which was discovered to be identified with degree of medication ingestion. In BCS, biowaivers depend on the degree of intestinal retention, which in various cases doesn't relate to intestinal permeability velocity.

Table- 1 Main Dissimilarity between BCS and BDDCS

	BCS	BDDCS
Aim	Potentiate biowaivers of <i>in vivo</i> bioequivalence considers.	Speculative assurance of medication attitude and medication drug cooperations in the digestive tract and liver.
Scale	Biowaivers are reliant upon the measure of intestinal ingestion (porousness), which in various cases doesn't associate with the pace of jejunal penetrability.	Hypothetical prediction are depends on intestinal permeability rate.

BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BDS)

It is an intelligent design for organizing drug molecules reliant upon their watery dissolvability and intestinal penetrability. It is a medication

improvement gadget that licenses evaluation of the responsibilities of three main issues, disintegration, solvency, and intestinal penetrability that impact oral prescription

absorption from IR solid oral portion structures. [2] It was first brought into the authoritative powerful cycle toward the path document on brief conveyance strong oral measurement structures: Scale-up and postapproval changes. [5] The prescriptions are isolated into high/low-dissolvability and vulnerability classes. By and by, BCS rules are given by WHO[7] USFDA [6], and EMEA. [8]

CLASS BOUNDARIES

Solubility

The dissolvability class limit relies upon the most essential bit strength of a medicine thing that is the part of a biowaivers (drug thing support without a pharmacokinetic bioequivalence study) request. As demonstrated by USFDA BCS bearing [6] a prescription substance is seen as significantly dissolvable when the most important bit strength is dissolvable in 250 ml or less of liquid media over the pH extent of 1-7.5. According to WHO bearing [7] an API is seen as incredibly dissolvable when the most raised bit (if the API appears on the WHO Model List of Essential Medicines) or most raised segment strength open accessible as an oral solid estimations structure (if the API doesn't appear on the WHO Model List of Essential Medicines) is dissolvable in 250 ml or less of watery media over the pH extent of 1.2-6.8. The pH-dissolvability profile of the API should be settled at 37 °C in liquid media. At any rate three reproducible decisions of dissolvability at each pH condition are proposed. Initial recommendations in the BCS Guidance

prescribed that the dissolvability should be assessed over a pH extent of 1.2-7.5. However, reformist consistent discussions and appropriations suggest that a pH extent of 1.2-6.8 is more reasonable. As demonstrated by EMEA BCS direction [8], a medicine substance is seen as significantly dissolvable if the most essential single part coordinated as IR formulation(s) is completely separated in 250 ml of pads inside the extent of pH 1-6.8 at 37 °C. This display requires the assessment in at any rate three backings inside this compass (preferably at pH 1.2, 4.5, and 6.8) and also at the pKa if it is inside the predefined pH range. At any rate, three copy decisions at each pH condition are recommended (e.g., shake-cup system or other shielded methods). Plan pH should be checked when the development of the drug substance to support.

Permeability

The permeability class limit based indirectly on the level of ingestion of a medicinal substance in individuals and directly on assessments of the speed of mass trade across the human intestinal layer. On the other hand, nonhuman structures prepared for expecting the level of drug ingestion in individuals can be used (e.g., in vitro epithelial cell culture techniques). As demonstrated by USFDA BCS direction, [6] without verification proposing precariousness in the GI part, a prescription substance is seen as uncommonly permeable when the level of ingestion in individuals is made plans to be 90% or a more prominent measure of a managed parcel reliant upon a mass balance confirmation or interestingly

with an intravenous reference partition. As demonstrated by the WHO course [7] an API is seen as extraordinarily vulnerable when the level of ingestion in individuals is 85% or more subject to a mass balance affirmation or in relationship with an intravenous comparator partition. The basic proposition in the BCS Guidance suggested an osmosis assessment of 90% as fundamental for the course of action as significantly permeable. In any case, reformist coherent discussions and legitimate circulations have prescribed releasing up the model to 85% maintenance for requesting an API as incredibly permeable. A commendable elective test method for vulnerability affirmation of the API could be in vivo intestinal perfusion in individuals. Right, when this system is used for infiltration inspects, the sensibility of the strategy should be shown, including affirmation of penetrability near with that of a reference build whose limited quantity of segment held has been accounted for to be at any rate 85%, similarly as the use of negative control. As shown by EMEA BCS direction [8] expecting a medicine substance has immediate and complete maintenance, it is considered particularly vulnerable.

Dissolution

According to USFDA BCS direction [6] and IR drug thing is considered rapidly dissolving when no under 85% of the stamped proportion of the medicine substance dissolves inside 30 minutes, using USP mechanical get together apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a volume of 900 ml or less in each medium: 0.1 N HCl or

reenacted gastric fluid USP without compounds; pad (pH 4.5); and support (pH 6.8) or replicated intestinal fluid USP without impetuses. As demonstrated by WHO BCS direction [7] a multisource thing (artificially same or synthetically elective things that may potentially be medicinally same) is seen as fast-dissolving when no under 85% of the checked proportion of the prescription substance separates in a matter of seconds using a paddle mechanical gathering at 75 rpm or a carton gadget at 100 rpm in a volume of 900 ml or less in each medium: HCl game plan (pH 1.2); acidic corrosive deduction pad (pH 4.5); and phosphate support (pH 6.8). A multisource thing is seen as fast-dissolving when no under 85% of the named proportion of the prescription substance separates in a brief timeframe using a paddle contraption at 75 rpm or a case mechanical get together at 100 rpm in a volume of 900 ml or less in all of the media: HCl plan (pH 1.2); acidic corrosive deduction support (pH 4.5); and phosphate pad (pH 6.8). According to EMEA BCS direction [8], drug things are seen as fast-dissolving when more than 85% of the named aggregate is separated instantly, using USP Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a volume of 500 ml in all of the media: 0.1 N HCl or emulated gastric fluid without compounds; pad (pH 4.5); and support (pH 6.8) or duplicated intestinal fluid without impetuses and equivalence of disintegration profiles should be shown.

CLASSIFICATION⁹

Table -2 Biopharmaceutics classification system

Class	Solubility	Permeability	Examples	Biowaiverity
I	High	High	Chloroquine, Diltiazem, Metoprolol, Paracetamol, Propranolol, Theophylline, Verapamil	Eligible for biowaivers
II	Low	High	Carbamazepine, Danazol, Glibenclamide, Ketoconazole, Nifedipine, Phenytoin, Troglitazone	Qualified for biowaivers as it were. On the off chance that feeble acids, profoundly dissolvable at Ph 6.8,+ dissolution
III	High	Low	Atenolol, Acyclovir, Captopril, Cimetidine, Neomycin B, Metformin, Ranitidine	Eligible for biowaivers If very rapidly dissolving
IV	Low	Low	Coenzyme Q10, Ritonavir, Cyclosporin A, Saquinavir, Ellagic acid, Furosemide, Taxol	Not eligible for biowaivers

DRUG EXPLORATION AND PRELIMINARY DEVELOPMENT [10, 27]

Bioavailability and Bioequivalence accept a central part in drug thing advancement and Bioequivalence examines are as of now being driven for New Drug Applications (NDAs) of new combinations, in favorable NDAs for new clinical signs and item offering developments, in Abbreviated NDAs of nonexclusive things, and in applications for the increase and postapproval changes. One of the major starting points put in the BCS measures to novel medicine substances is that first thing in preformulation/plan, the segment

isn't yet correctly known. Thusly, presently, the Dose to Solubility extent (D:S) should be conveyed as a plausible reach. Collects with more than 100 mg/ml liquid solvency just at times show dissolution rate-limited maintenance. Then again, one can survey the most limited absorbable segment dependent on the standard GI fluid volumes available under the normal dosing conditions and the medicine solubility. In stress with the solubility of the medicine, it may be significant to consider the physicochemical properties of the medicine while picking which media to use for the solubility decisions. For

example, assessing solubility at all pH regards recommended by the BCS is inconsequential for unprejudiced blends in the early new development. A while later, when subtleties are pondered, dissolution data for the drug thing strange gastrointestinal pH arrive freely be useful in setting up the goodness of conveyance from the definition under gastrointestinal conditions. Lipid loving drugs may be ineffectually solubility in water and in fundamental backings, yet in the gastrointestinal fluids, the bile has a tremendous degree that routinely solubilize them. Developments in solubility of 1 to 2 critical degrees is serviceable for admixtures with log P assessments of 4. For auspicious blends that do both lipids love and ionizable, expansive solubility investigates in bio-significant media will help with portraying the believable solubility direct in-vivo. Alternative philosophy is to use forces of pull from human participants, regardless of the way that volumes suctioned usually are pretty much nothing, and the determination of preliminaries and contraption, thusly, is in a like manner limited. The following issue is the usage of 250 ml as the volume wherein a bit ought to be separated. This entirety is a moderate check of the volume of fluid open in the gut under fasting-state conditions and relies upon the volume, generally, ingested close by the portion structure in ADME study. Dependent on whether drug association is to be on an unfilled abdomen or with meals, it is huge and reasonable to change the volume used to assess the constraint of the gastrointestinal fluids to separate the segment. A proposed early phase is

to use a quantity of around 300 ml for the declined stomach, around 500 ml for the fasting little stomach related parcel, and up to 1 ml for the postprandial stomach and little stomach related framework. The choice of the model for looking over the porousness is similarly of thought. The CACO-2 cells can be used to assess transcellular scattering and can be standardized to ensure reproducible results, notwithstanding, they will, as a rule, put down paracellular and dynamic frameworks, can't be used to choose regional penetrability inside the gut, and will, when all is said in done, overestimate efflux through the P-glycoprotein's. In situ insertion in rodents, despite the way that they are extraordinarily improved similarly as expecting dynamic vehicle and can be used to choose neighborhood vulnerability, take extra time and effort to make a strong porousness check consequently in any case, it is a brilliant idea to have more than one vulnerability screen at the evacuation of the lab to join sureness and goodness into the screening system. If the solubility of the prescription is the issue rather than its vulnerability, plan tries should point increasing the dissolution profile. For example, the combined effects of characterizing the medicine as vague solid dispersing and directing it in the fed stage will in an overall move the dissolvability disintegration credits from those of an insufficiently dissolvable drug (D:S -10000 ml) to those of a medication thing with a D:S inside the extent of characteristics experienced in the gut after meals. If the vulnerability of the drug, rather than solvency, is the essential issue, plan

approaches are less different and less strong. Regardless, when the settlement is made for the qualifications permeability and solubility necessities for vocal drug thing improvement inverse biowaivers models according to the BCS, further factors really ought to be considered for new medications. These segments join the opportunity of decay under gastrointestinal environment and the evaluation of the chief pass assimilation in the liver and the gut divider. Evaluating dissolution in the intestine is tolerably clear using bio-applicable media and transparency times reliant upon longest expected receptiveness times. For sensitive blends, legitimate synthetic compounds ought to be added to the medium in relevant obsessions. The impetuses that can be sensible are gastric lipases and pepsin for the stomach, pancreatic mixtures for the jejunum and bacterial synthetic substances for the end of the large intestine. By virtue of the chief pass processing in the gut divider, it may be achievable to assess for metabolic products in the penetrability model dependent upon how the model is construct.

BIOPHARMACEUTICS DRUG DISPOSITION CLASSIFICATION SYSTEM (BDDCS)

As depicted over, the justification BDDCS is to predict drug aura and potential medication communications in the stomach related plot and the liver with a highlight on portraying which meds would be pleasing to enzymatic-just and transporter just way and medicine connections, similarly as where transporter compound trade

may be huge. Continuous overviews from the Benet Lab [28-30] have described these enzymatic, transporter, and transporter exchange characteristics with potential transporter impacts following oral dosing as depicted in Figure 1. The affirmation of the association between's BCS intestinal porousness and BDDCS level of processing by Wu and Benet [3] went before an explanation for these disclosures. We surmise since high-porousness rate collects are immediately reabsorbed from the bile and from the kidney lumen, working with various gets to the metabolic synthetics. For example, consider the BCS/BDDCS Class 1 medicine letrozole. This absolutely oral available prescription is essentially discarded by digestion through CYP2A6 and CYP3A4 enzymatic cycles with less than 4% of the segment released unaltered in the pee. In any case, letrozole is essentially 60% joined to plasma proteins and consequently it might be ordinary, considering glomerular filtration rate and part unbound, that renal space could push toward 48 mL/min. However the total slack for letrozole is simply 40.5 mL/min with less than 4% released unaltered. Thusly, this high-porousness molecule is reabsorbed in the kidney tubules (and maybe from the bile) with the huge course of removal being metabolic cycles. The thinking for the association between's intestinal porousness rate and the level of digestion has every one of the reserves of being established in transit that high penetrability rate fabricates are reabsorbed from potential unaltered medicine release courses in the body and therefore should be discarded through

digestion. This theory by then drove us to reason that the extent of high-penetrability rate in making the BDDCS task need not actually be a human

natural film or layer intermediary; anyway that latent porousness in any appropriate film model may give the correct undertaking.

Figure- 1. Transporter effects concluded by BDDCS following oral drug administration.²⁸

	High solubility	Low solubility
High permeability/ metabolism	Class 1 Transporter effects minimal in gut and liver	Class 2 Efflux transporter effects predominate in gut, but both uptake & efflux transporters can affect liver
Low permeability/ metabolism	Class 3 Absorptive transporter effects predominate (but can be modulated by efflux transporters)	Class 4 Absorptive and efflux transporter effects could be important

THE ROLE OF BDDCS IN THE DRUG PROGRESS OF NEW MOLECULAR ENTITIES (NMEs)

In spite of the fact that BDDCS can be utilized for describing the disposition of medications effectively available. The objective of BDDCS was to anticipate and portray drug disposition for new molecular entities [3]. BDDCS is used with NMEs to anticipate the significant way of elimination of NMEs in people, predict the importance of carriers and carrier enzyme transaction in drug disposition as itemized in Figure-1 and Table-2. Foresee focal or absence of focal impacts. Foresee the impacts of more-fat foods on the degree and amount of bioavailability.

CONCLUSION

The BCS and BDDCS go probably as an admirable endeavor for the improvement of different oral drug transport structures and progressions. The BCS gives a task into three main issues, dissolution, solvency, and intestinal penetrability, which manage the rate and level of drug retention from IR dosage in solid form. BCS permits drug fashioners to manage the development or physiochemical properties of lead drug things. The techniques given by the BCS are detraction of medicine receptiveness to the colossal leading group of human topics and occasionally, curtailed prescription thing headway time in like manner of huge cost speculation reserves. BDDCS could fill in as a justification predicting the meaning of transporters in choosing

the prescription way, similarly as in expecting drug-drug associations.

CONFLICT OF INTEREST

Authors don't have any conflict of interest

REFERENCES

1. Food and Drug Administration. 2000. Guidance for industry: Waiver of *in vivo* bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Rockville, Maryland: Food and Drug Administration. Accessed October 20, 2012, at: www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219.htm.
2. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutics drug classification: The correlation of *in vitro* drug product dissolution and *in vivo* bioavailability. *Pharm Res* 12:413–420.
3. Wu C-Y, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. *Pharm Res* 22:11–23.
4. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. 2012. BDDCS class prediction for new molecular entities. *Mol Pharm* 9:570–580
5. Center for Drug Evaluation, USFDA. Guidance for Industry: Immediate Release Solid Oral Dosage Forms: Scale Up and Post Approval Changes. Nov 1995.
6. Center for Drug Evaluation, USFDA. Guidance for industry: Waiver of *In vivo* bioavailability and bioequivalence for immediate release solid oral dosage forms based on a biopharmaceutics classification system. August 2000.
7. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report. Geneva, World Health Organization. WHO Technical Report Series, No. 937, Annex 7: 2000. p. 347-390
8. Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1), July 2008.
9. Chavda HV, Patel CN, Anand IS. 2010. Biopharmaceutics Classification System, *Sys Rev Pharm | January-June 2010 | Vol 1 | Issue 1*
10. Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: Where do we go from here? *PharmaceutTechnol* 2001;25:68-76.

11. Gothoskar AV. Biopharmaceutical classification system of drugs [online]. Pharmaceut Rev. Availablen from: URL: <http://www.pharmainfo.net/reviews/biopharmaceutical-classification-drugs>. [last cited on 2005 Feb 12].
12. Center for Drug Evaluation, USFDA. Guidance for industry: Waiver of *In vivo* bioavailability and bioequivalence for immediate release solid oral dosage forms based on a biopharmaceutics classification system. August 2000.
13. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report. Geneva, World Health Organization. WHO Technical Report Series, No. 937, Annex 7: 2000. p. 347-390.
14. Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1), July 2008.
15. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharmaceut Res 1991;8:979-88.
16. Lennernäs H, Knutson L, Knutson T, Hussain A, Lesko L, Salmonson T, et al. The effect of amiloride on the *in vivo* effective permeability of amoxicillin in human jejunum: Experience from a regional perfusion technique. Eur J Pharm Sci 2002;15:271-7.
17. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-11.
18. Farthing MJ. Disease-related animal models for optimising oral rehydration solution composition. ActaPaediatr 2008;78:23-30.
19. Scherer D, Mooren FC, Kinne RK, Kreuter J. *In Vitro* permeability of PBCA nanoparticles through porcine small intestine. J Drug Target 1993;1:21-7.
20. Yee S. *In Vitro* permeability across *Caco-2* cells (colonic) can predict *in vivo* (small intestinal) absorption in man-fact or myth. Pharm Res 1997;14:763-6.
21. Grès MC, Julian B, Bourrié M, Meunier V, Roques C, Berger M, et al. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental *Caco-2* cell line. Pharm Res 1998;15:726-33.
22. Center for Drug Evaluation, USFDA. Guidance for Industry: Immediate Release

- Solid Oral Dosage Forms: Scale Up and Post Approval Changes. Nov 1995.
23. Kanfer I. Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice. *J Pharm PharmSci* 2002;5:1-4.
24. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS) literature data: Chloroquine phosphate, chloroquinesulfate, and chloroquine hydrochloride. *J Pharm PharmSci* 2005;94:1389-95.
25. Nagesh XB, Murti V. BCS Class IV Drugs: Develop or Discard? AAPS annual meeting and Exposition; 2007 Nov 11-15; San Diego Convention Centers, San Diego, CA.
26. Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U, Ravi Kumar MN. Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. *Nanotechnology* 2005;16:2819-22.
27. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying Drug Delivery Systems (SEDDS) of Coenzyme Q10: Formulation development
28. Shugarts S, Benet LZ. 2009. The role of transporters in the pharmacokinetics of orally administered drugs. *Pharm Res* 26:2039–2054.
29. Benet LZ. 2009. The drug transporter-metabolism alliance: Uncovering and defining the interplay. *Mol Pharm* 6:1631–1643.
30. Benet LZ. 2010. Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. *Basic Clin Pharmacol Toxicol* 106:162–167.

Received: 10 Feb, 2021, Decision for Acceptance: 20 Mar, 2021

Cite this article

TejpalYadav. Biopharmaceutics Classification System (BCS) and Biopharmaceutics Drug Disposition Classification System (BDDCS) – An Approach for Drug Development and Advancement, *Indian Journal of Healthcare, Medical & Pharmacy Practice*. 2021; 2(1):14-24.